IL-17 mobilizes the granulocyte-colony stimulating factor (G-CSF)-dependent recruitment of CD11b+Gr1+ immature myeloid cells, involved in anti-VEGF tumor refractoriness [47]. The gene discussed is CSF3; the disease is neoplasm.